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Abstract
Renal transplantation in patients affected by hepatitis C virus (HCV) infection has been a serious problem because of the use of immunosup-
pressants. HCV virus may be more aggressive in both the liver and the kidney. Several posttransplantation pathologies are known to be ascribed 
to the HCV virus. Virus eradication has been historically attempted with interferon (IFN) and ribavirin with poor results. In addition, IFN given 
posttransplantation may cause severe acute rejection. The introduction of direct antiviral agents (DAA) has revolutionized the treatment, and 
now it is possible to treat renal transplant patients with these agents leading to a HCV-free status in 3 months without the use of IFN. The major 
problem caused by these agents is their interference with the immunosuppressive agents. The pharmacokinetics of DAA and immunosuppres-
sants often meet the same metabolic pathways and use the same cytochromes or proteic complexes. In some cases, this may lead to high or low 
immunosuppressant levels with the risk of rejection. In other cases, the DAAs are interested and they may be increase or decrease in a dangerous 
way. Therefore, a strict monitoring is always recommended.
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Introduction
Carta et al. published an interesting article on the use of 
some direct antiviral agents (DAAs) in renal transplant (RT) 
recipients affected by hepatitis C virus (HCV) infection.
The issue is relevant and presents several aspects that need 
to be highlighted.
Clinical Problems of HCV in RT Patients
The persistence of HCV infection after RT is a severe risk 
factor for graft and patient survival. Complications may 
involve the liver or the kidney.
Maurizio Salvadori and Aris Tsalouchos
 Journal of Renal and Hepatic Disorders 2020;4(2):29–33 30
glomerulopathy (the marker of chronic rejection) devel-
oped significantly earlier posttransplantation in HCV+ 
RT patients with respect to HCV – patients (P = 0.02). The 
authors documented an overlapping of chronic humoral 
rejection, HCV infection, and thrombotic microangiopathy.
  Finally, it is important to remember the high incidence 
of acute rejection in transplant patients receiving inter-
feron (IFN) (9).
  All these findings support the relevance of treating 
HCV infection in RT patients and the need to find alter-
native and more effective therapies with respect to IFN.
DAA-Based Therapies
The improved knowledge of the vital cycle of HCV and of 
the virus structure and its proteins allowed the development 
of highly efficient DAA (Figure 1).
To date, the DAAs may be divided into four classes accord-
ing to the mechanism of action (Table 1). The first DAAs for 
the treatment of HCV were the protease inhibitors against 
NS3/SA, such as telaprevir and boceprivir (10, 11). These 
drugs are used for the treatment of genotype 1 in associa-
tion with IFN and ribavirin. In 2013, three new DAAs were 
approved in the United States: simeprivir (IP-NS3/NS4A), 
daclatasvir (inhibitor of NS5A), and sofosbuvir (inhibitor 
of polymerase NS5B). The use of these DAAs allowed for 
avoiding the use of IFN. New strategies in the use of DAAs 
have been the use of combinations of DAAs (12), such as 
sofosbuvir and ledipasvir. More recently, new DAAs have 
been added, such as elbasvir, glecaprevir, ritonavir, ombitas-
vir, dasabuvir, and voxilaprevir (13, 14).
The introduction of these drugs allowed for obtain-
ing efficacy against all genotypes, to reduce the duration 
Liver disease
The immunosuppression is associated with an increase 
in viral replication and with a progression of hepatic 
 fibrosis  (1). The same study documented that the evolution 
toward cirrhosis was 21.4% in transplant patients versus 
3.6% in nontransplant patients.
Renal disease
1. Secondary infections
 RT patients HCV+ have a higher incidence of systemic 
infections, in particular affecting the central nervous sys-
tem and the respiratory tract. These infections in these 
patients represent the second most common cause of 
patient deaths after hepatic disease (2).
2. Posttransplant diabetes mellitus (NODAT)
 In one meta-analysis on 30,099 RT patients, the prevalence 
of diabetes mellitus was higher in HCV+ patients (3).
3. Lymphoproliferative disorders
 Several studies documented an increase of lymphoprolif-
erative disorders in HCV+ RT patients (4).
4. Glomerulonephritis
 HCV with associated cryoglobulinemia frequently causes 
membranoproliferative glomerulonephritis (MPGN) 
after RT (5). In this study, MPGN was found in 45.4% 
of RT patients who were HCV+. HCV+ is also associ-
ated with membranous nephropathy (MN) after RT (6). 
Both MPGN and MN can be ascribed to the deposition 
of immunocomplexes containing viral RNA (7).
5. Transplant glomerulopathy
 One study from the Boston study group (8) stud-






















Figure 1. Development of new drugs for HCV infection. HCV, hepatitis C virus.
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Table 1: The four classes of DAAs.
The four classes of DAAs Mechanism of action Drugs (targeted genotypes in brackets)
NS3/4A protease inhibitors
(PIs)
Block a viral enzyme (protease) that enables 






Nucleoside and nucleotide 
NS5B polymerase inhibitors
Target the hep C virus to stop it from 
replicating itself  in the liver, thereby 
blocking the virus from multiplying
• Sofosbuvir (1–4)
NS5A inhibitors Block a virus protein, NS5A, that HCV 









Nonnucleoside NS5B  
polymerase inhibitors
Stop HCV from reproducing by inserting 
themselves into the virus so that other 
pieces of the hep C virus cannot attach to it
• Dasabuvir (1)
DAA, Direct-Acting-Antivirals; HCV, hepatitis C virus; hep C, hepatitis C.
of treatment, and to increase the safety and efficacy of the 
treatment (15).
The new KDIGO guidelines recommend that all patients 
with HCV who are candidates for kidney transplantation 
should be considered for DAA therapy, either before or after 
transplantation. The same recommendation applies to HCV 
candidates with a living donor (16).
Pharmacological Interactions
Pharmacokinetic interactions are the most important, pri-
marily because of the role of cytochrome P450 (CYP450). 
The interactions with glycoprotein P (P-gp) are also import-
ant in limiting the drug bioavailability (17, 18).
The use of drugs inducing CYP450 or P-gp carries the risk 
of reducing the DAA concentrations. On the other hand, 
the use of the protein inhibitor, NS3-4A, is contraindicated 
in patients with severe liver disease. Similarly, the use of the 
polymerase inhibitor, sofosbuvir, is not indicated in patients 
with estimated glomerular filtration rate (eGFR) < 30 mL/
min/1.73 m2 because of its renal elimination (19).
In addition to inhibiting cytochrome CYP3A, cyclosporine 
(CyA) also inhibits the organ anion transporter family 1B1/3 
(OATP1B1/3), the breast cancer resistance protein (BCRP), 
and P-gp. As a consequence, its administration with a pro-
tease inhibitor IPNSA3-4A is not recommended because of 
the increase in blood CyA. On the contrary, the administra-
tion of simeprevir with tacrolimus (TAC) causes only a small 
decrease of the latter and requires monitoring (20, 21).
The new combinations with an IPNS3-4A as grazoprevir– 
elbasvir or glecaprevir–pibrentasvir or sofosbuvir– 
ledipasvir–voxilaprevir may cause a mild TAC modification 
and require monitoring (22–24).
No data are available for the inhibitors of mammalian tar-
get of rapamycin (mTORIs).
Daclatasvir and sofosbuvir may be safely administered 
together with TAC and mTORIs (25).
The association between ombitasvir–paritaprevir– 
ritonavir and the immunosuppressants may be dangerous 
because ritonavir causes inhibition of CYP3A4 and of P-gp. 
This may cause an increase of the calcineurin inhibitors and 
of the mTORIs. In one study (26), CyA doses were reduced 
to one-fifth and TAC doses were reduced to 0.5 mg/week.
Table 2 shows the modifications of immunosuppressant 
doses in patients receiving DAA.
In conclusion, the availability of new IFN-free DAA offers 
the possibility of efficiently treating RT patients with HCV 
infection.
The possible important interactions between these drugs 
and the immunosuppressants often require strict monitor-
ing to reduce the risks of rejection or immunosuppressants- 
related toxicity.
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